JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

A case of autoimmune retinopathy associated with thyroid carcinoma.

PURPOSE: To report a case of autoimmune retinopathy (AIR) associated with a thyroid carcinoma.

DESIGN: Case report.

METHOD: A 51-year-old Caucasian woman presented with a rapid decline in vision. Initial visual field and immunohistochemical testing revealed autoimmune retinopathy without an apparent underlying malignancy. Conventional local and systemic immunosuppressive therapies failed to halt the progression.

RESULTS: Rituximab treatments were initiated and a slowing of visual loss was seen. Continued surveillance for malignancy revealed a thyroid adenoma, and later a thyroidectomy revealed a thyroid carcinoma.

CONCLUSIONS: This report highlights the unique presentation of AIR associated with a thyroid carcinoma, the need for continued surveillance for malignancy in cases of AIR, and the possible new use of rituximab for the treatment of AIR.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app